Aclacinomycin A in the treatment of multiple myeloma: a Southwest Oncology Group study.
Aclacinomycin A in the treatment of multiple myeloma: a Southwest Oncology Group study.
复制标题
阿克拉霉素 A 治疗多发性骨髓瘤：西南肿瘤小组的一项研究。
DOI：
10.1007/bf00216933
复制
发表时间：
1990
影响因子：
3.4
通讯作者：
Salmon,S
中科院分区：
文献类型：
--
作者：
Karanes,C;Crowley,J;Sawkar,L;Tranum,BL;Hicks,WJ;Bonnet,JD;Dabich,L;Dana,BW;Salmon,S
52例进展性耐药多发性骨髓瘤患者进入了西南肿瘤组的II期研究，每周静脉注射阿克拉霉素a。在43例可评估的患者中，有1例持续2年的部分缓解，2例持续的临床改善，副蛋白减少了25%。观察到的主要毒性是严重的骨髓抑制和明显的恶心和呕吐，需要减少剂量和延迟预定的治疗。1例患者出现心律失常。建议在未来的研究中长期每日或连续静脉输注。
Fifty-two patients with progressive resistant multiple myeloma were entered in this Southwest Oncology Group Phase II study, using weekly intravenous Aclacinomycin A. Of forty-three evaluable patients for response, there was one partial remission of 2 years duration and two sustained clinical improvements with 25% reduction in paraprotein. Major toxicity seen was severe myelosuppression and significant nausea and vomiting requiring dose reduction and delay of the scheduled treatment. Cardiac arrhythmia was seen in one patient. Chronic daily schedule or continuous IV infusion is recommended for future study.